Haur Yueh Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7866692/publications.pdf

Version: 2024-02-01

88 papers 1,807 citations

257450 24 h-index 40 g-index

88 all docs 88 docs citations

88 times ranked 2059 citing authors

#	Article	IF	Citations
1	U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016. British Journal of Dermatology, 2016, 174, 1194-1227.	1.5	199
2	Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. British Journal of Dermatology, 2017, 177, 924-935.	1.5	110
3	The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre. British Journal of Dermatology, 2013, 169, 1304-1309.	1.5	95
4	Pembrolizumab-induced Stevens–Johnson syndrome in non-melanoma patients. European Journal of Cancer, 2017, 81, 237-239.	2.8	88
5	Cytokines and Chemokines in Irritant Contact Dermatitis. Mediators of Inflammation, 2013, 2013, 1-7.	3.0	85
6	UK guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2016, 69, e119-e153.	1.0	67
7	The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. British Journal of Dermatology, 2012, 167, 555-562.	1.5	64
8	Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center. Journal of the American Academy of Dermatology, 2017, 76, 106-113.	1.2	64
9	The Medication Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label. Clinical Pharmacology and Therapeutics, 2019, 105, 112-120.	4.7	54
10	Epidermal necrolysis: 60Âyears of errors and advances. British Journal of Dermatology, 2015, 173, 1250-1254.	1.5	53
11	Antibiotic prophylaxis for preventing recurrent cellulitis: A systematic review and meta-analysis. Journal of Infection, 2014, 69, 26-34.	3.3	50
12	Toxic epidermal necrolysis. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 330-336.	2.3	43
13	Determining the Incidence of <i>Pneumocystis</i> Pneumonia in Patients With Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis. JAMA Dermatology, 2017, 153, 1137.	4.1	43
14	Management of epidermal growth factor receptor tyrosine kinase inhibitorâ€related cutaneous and gastrointestinal toxicities. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 23-31.	1.1	43
15	Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study. Pharmacogenomics Journal, 2014, 14, 316-321.	2.0	40
16	Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis. Osteoporosis International, 2009, 20, 161-162.	3.1	38
17	Melanoma: differences between Asian and Caucasian patients. Annals of the Academy of Medicine, Singapore, 2012, 41, 17-20.	0.4	35
18	Multimorbidity in bullous pemphigoid: a case–control analysis of bullous pemphigoid patients with age―and genderâ€matched controls. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1709-1714.	2.4	32

#	Article	IF	Citations
19	Systemic lupus erythematosus presenting as Stevens–Johnson syndrome and toxic epidermal necrolysis: a report of three cases. Lupus, 2011, 20, 647-652.	1.6	31
20	Dermatology referrals in an East Asian tertiary hospital: a need for inpatient medical dermatology. Clinical and Experimental Dermatology, 2011, 36, 129-134.	1.3	31
21	Cellulitis Recurrence Score: A tool for predicting recurrence of lower limb cellulitis. Journal of the American Academy of Dermatology, 2015, 72, 140-145.	1.2	31
22	Acute generalized exanthematous pustulosis: analysis of cases managed in a tertiary hospital in Singapore. International Journal of Dermatology, 2010, 49, 507-512.	1.0	30
23	Amicrobial Pustulosis-Like Rash in a Patient with Crohn's Disease under Anti-TNF-Alpha Blocker. Dermatology, 2011, 222, 304-310.	2.1	30
24	Infectious complications in bullous pemphigoid: An analysis of risk factors. Journal of the American Academy of Dermatology, 2015, 72, 834-839.	1.2	29
25	Assessment and Comparison of Performance of ABCD-10 and SCORTEN in Prognostication of Epidermal Necrolysis. JAMA Dermatology, 2020, 156, 1294.	4.1	25
26	Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients. Journal of the American Academy of Dermatology, 2019, 81, 686-693.	1.2	24
27	The association between drugs and bullous pemphigoid. British Journal of Dermatology, 2017, 176, 549-551.	1.5	21
28	Allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis. Journal of the American Academy of Dermatology, 2008, 59, 352-353.	1.2	20
29	Cutaneous follicular hyperkeratotic spicules – the first clinical sign of multiple myeloma progression or relapse. International Journal of Dermatology, 2010, 49, 934-936.	1.0	20
30	A phase Ib safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib (gef) in EGFR TKI-resistant NSCLC Journal of Clinical Oncology, 2013, 31, 8107-8107.	1.6	18
31	UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermalÂnecrolysis in adults 2016 (print summary – Full guidelines available at http://dx.doi.org/10.1016/j.bjps.2016.01.034). Journal of Plastic, Reconstructive and Aesthetic Surgery, 2016, 69, 736-741.	1.0	17
32	Improvement of Mortality Prognostication in Patients With Epidermal Necrolysis. JAMA Dermatology, 2022, 158, 160.	4.1	17
33	Oral Mucous Membrane Pemphigoid: Complete Response to Topical Tacrolimus. Acta Dermato-Venereologica, 2011, 91, 604-605.	1.3	16
34	Initial Presentation of DRESS: Often Misdiagnosed as Infections. Archives of Dermatology, 2012, 148, 1085.	1.4	16
35	Rare case of type I hypersensitivity reaction to sodium hypochlorite solution in a healthcare setting. BMJ Case Reports, 2016, 2016, bcr2016217228.	0.5	16
36	Increased risk of strontium ranelate-related SJS/TEN is associated with HLA. Osteoporosis International, 2016, 27, 2577-2583.	3.1	16

#	Article	IF	Citations
37	Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach. Pharmacogenomics, 2017, 18, 881-890.	1.3	15
38	Clinical outcomes of bacteraemia in cellulitis of the leg. Clinical and Experimental Dermatology, 2014, 39, 683-688.	1.3	14
39	The association of obstructive sleep apnea with melanoma incidence and mortality: a meta-analysis of 5,276,451 patients. Sleep Medicine, 2021, 88, 213-220.	1.6	13
40	Epidemiology of Stevens–Johnson syndrome and toxic epidermal necrolysis in Southeast Asia. Dermatologica Sinica, 2013, 31, 217-220.	0.5	12
41	Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: An unmet need. Journal of the American Academy of Dermatology, 2018, 79, e87-e88.	1.2	12
42	Acute generalized exanthematous pustulosis: Epidemiology, clinical course, and treatment outcomes of patients treated in an Asian academic medical center. JAAD International, 2021, 3, 1-6.	2.2	11
43	Ashy dermatosis (erythema dyschromicum perstans) induced by omeprazole: a report of three cases. International Journal of Dermatology, 2015, 54, e435-6.	1.0	10
44	Subacute cutaneous lupus erythematosus after immunotherapy for renal-cell carcinoma: the case for interferon-alpha. Clinical and Experimental Dermatology, 2009, 35, 491-492.	1.3	7
45	All-trans retinoic acid-induced scrotal ulcer in a patient with acute promyelocytic leukaemia. Clinical and Experimental Dermatology, 2010, 35, 91-92.	1.3	7
46	Dermatological conditions seen in renal transplant recipients in a Singapore tertiary hospital. Singapore Medical Journal, 2018, 59, 519-523.	0.6	7
47	Pilot study of a customized nanotextile wet garment treatment on moderate and severe atopic dermatitis: A randomized clinical trial. Pediatric Dermatology, 2020, 37, 52-57.	0.9	6
48	Diabetes mellitus and hyperglycemic complications in bullous pemphigoid. Journal of the American Academy of Dermatology, 2020, 82, 1234-1237.	1.2	6
49	Mycoplasma-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: Case-control analysis of a cohort managed in a specialized center. Journal of the American Academy of Dermatology, 2021, , .	1.2	6
50	Therapy-related Leukemia Cutis after Adjuvant Chemotherapy in a breast cancer patient. Acta Dermato-Venereologica, 2010, 90, 649-650.	1.3	5
51	Spectrum of Nail Sequelae in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatology, 2021, 157, 117.	4.1	5
52	Intravascular large B-cell lymphoma presenting as panniculitis clinically: a case report. Singapore Medical Journal, 2018, 59, 163-164.	0.6	5
53	Sequential Stevens–Johnson syndrome and photoâ€recall phenomenon. British Journal of Dermatology, 2012, 166, 1145-1146.	1.5	4
54	Flexural eruption in two hospitalized patients. Clinical and Experimental Dermatology, 2013, 38, 943-945.	1.3	4

#	Article	IF	Citations
55	Erythema ab igne und dermale Vernarbung durch Schr $ ilde{A}\P$ pfen und Moxibustionsbehandlung. JDDG - Journal of the German Society of Dermatology, 2015, 13, 337-338.	0.8	4
56	Papuloerythroderma of Ofuji presenting as a paraneoplastic phenomenon in myelodysplastic syndrome. Australasian Journal of Dermatology, 2018, 59, e155-e156.	0.7	4
57	Early experience of inpatient teledermatology in Singapore during COVID-19. Annals of the Academy of Medicine, Singapore, 2021, 50, 487-489.	0.4	4
58	Relationship between local weather, air pollution and hospital attendances for urticaria in children: Time stratified analysis of 12,002 cases. Clinical and Experimental Allergy, 2022, 52, 180-182.	2.9	4
59	Acrylateâ€induced hand dermatitis in the manufacture of contact lenses. Contact Dermatitis, 2009, 61, 117-118.	1.4	3
60	Erythema ab igne and dermal scarring caused by cupping and moxibustion treatment. JDDG - Journal of the German Society of Dermatology, 2015, 13, 337-338.	0.8	3
61	How different is Stevens–Johnson syndrome/toxic epidermal necrolysis in children?. British Journal of Dermatology, 2019, 181, 10-11.	1.5	3
62	Spectrum of dermatological conditions seen in the intensive care unit. Clinical and Experimental Dermatology, 2016, 41, 920-921.	1.3	2
63	Psychological sequelae of toxic epidermal necrolysis: further insights. British Journal of Dermatology, 2016, 175, 241-241.	1.5	2
64	Stevens–Johnson syndrome/toxic epidermal necrolysis: a chronic condition?. British Journal of Dermatology, 2020, 182, 826-827.	1.5	2
65	Carbamazepine-induced toxic epidermal necrolysis in a patient despite testing negative for HLA B*15:02 allele. Annals of the Academy of Medicine, Singapore, 2021, 50, 258-260.	0.4	2
66	Delayed admission to a specialist referral center for Stevens-Johnson syndrome and toxic epidermal necrolysis is associated with increased mortality: A retrospective cohort study. JAAD International, 2021, 4, 10-12.	2.2	2
67	Treatment of eczematoid and vitiliginous graft versus host disease with extracorporeal photopheresis and alemtuzumab. Journal of the American Academy of Dermatology, 2013, 68, AB142.	1.2	1
68	Eruptive nodules in a patient with marginal zone lymphoma. Clinical and Experimental Dermatology, 2014, 39, 949-951.	1.3	1
69	Acute generalized exanthematous pustulosis (AGEP) in Singapore. Clinical and Translational Allergy, 2014, 4, P90.	3.2	1
70	Multiple drug hypersensitivity associated with severe cutaneous adverse reaction. Clinical and Translational Allergy, 2014, 4, P135.	3.2	1
71	Internet and smartphone application usage in eating disorders: A descriptive study in Singapore. European Psychiatry, 2016, 33, S166-S167.	0.2	1
72	Eating disorders in Malays in Singapore. European Psychiatry, 2017, 41, S554-S554.	0.2	1

#	Article	IF	CITATIONS
73	Long-standing Pica with compulsive features in a woman with iron and zinc deficiency. European Psychiatry, 2017, 41, S554-S554.	0.2	1
74	Recurrence of Stevens–Johnson syndrome and toxic epidermal necrolysis in adults. International Journal of Dermatology, 2017, 56, e78-e79.	1.0	1
75	Pemphigoid and pemphigus: Comparative analysis of clinical epidemiology, course and outcome in an Asian Academic Medical Centre. Australasian Journal of Dermatology, 2021, 62, e288-e290.	0.7	1
76	Rapid Desensitization for Insulin Allergy in Type 1 Diabetes Using an Insulin Pump: A Case Report and Literature Review. AACE Clinical Case Reports, 2021, 7, 346-349.	1.1	1
77	Bullous pemphigoid: towards personalized care. British Journal of Dermatology, 2021, , .	1.5	1
78	Cutaneous Presentation of Angioimmunoblastic T-Cell Lymphoma: A Harbinger of Poor Prognosis?. Skinmed, 2016, 14, 469-471.	0.0	1
79	Reply to: "A potential underestimation of the number of cellulitis recurrences in study― Journal of the American Academy of Dermatology, 2015, 72, e129.	1.2	O
80	Blistering Eruption of the Buttocks. JAMA Dermatology, 2015, 151, 1367.	4.1	0
81	Treatment of overlap cutaneous graftâ€versusâ€host disease with combination therapy of extracorporeal photopheresis and alemtuzumab. International Journal of Dermatology, 2016, 55, 335-338.	1.0	O
82	Bulimia nervosa in Singapore: Clinical profile, comorbidity and gender comparisons. European Psychiatry, 2017, 41, S561-S562.	0.2	0
83	The use of intravenous immunoglobulins in Stevens–Johnson syndrome and toxic epidermal necrolysis: caution needed. International Journal of Dermatology, 2017, 56, e27-e28.	1.0	O
84	Reply to: "The age of procalcitonin: Potential pitfalls in critically ill patients with SJS/TEN. A comment on †Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients'― Journal of the American Academy of Dermatology, 2020, 82, e249.	1.2	0
85	Erythematous papular eruption of acute onset in a 51â€yearâ€old male. International Journal of Dermatology, 2021, 60, 953-955.	1.0	O
86	Melanoma in Singapore: Putting our best foot forward!. Annals of the Academy of Medicine, Singapore, 2021, 50, 454-455.	0.4	0
87	Melanoma in Singapore: Putting our best foot forward!. Annals of the Academy of Medicine, Singapore, 2021, 50, 454-455.	0.4	0
88	Injection site reactions after COVID-19 mRNA vaccination. Annals of the Academy of Medicine, Singapore, 2022, 51, 247-249.	0.4	0